1
|
Wong A, Ahuja T, Cirrone F, Xiang E. Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center. J Oncol Pharm Pract 2024; 30:246-250. [PMID: 37132025 DOI: 10.1177/10781552231173138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Romiplostim is indicated for immune thrombocytopenia (ITP), though is often used off-label for other indications such as chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia post hematopoietic stem cell transplantation (HSCT). Although romiplostim is FDA approved at a starting dose of 1 mcg/kg, it is often initiated at 2-4 mcg/kg depending on the severity of thrombocytopenia in clinical practice. Given the limited data, but interest in higher doses of romiplostim for indications other than ITP, we aimed to assess our inpatient romiplostim utilization at NYU Langone Health.This was a single-center, retrospective review of 84 adult patients from January 2019 to July 2021. The top three indications were ITP (51, 60.7%), CIT (13, 15.5%), and HSCT (10, 11.9%). The median initial romiplostim dose was 3.8 mcg/kg (range, 0.9-10.8). 51% of patients achieved a platelet count of ≥50 × 109/L by the end of week 1 of therapy. For patients achieving goal platelets by the end of week 1, the median dose of romiplostim was 2.4 mcg/kg (range, 0.9-10.8). There was 1 episode of thrombosis and 1 episode of stroke.We found that higher than FDA-recommended initial doses should be considered to achieve a platelet response. It appears to be safe to initiate romiplostim as higher doses, and to increase doses by greater increments than 1 mcg/kg in order to achieve a platelet response. Future prospective studies are needed to confirm the safety and efficacy of romiplostim in off-label indications and should evaluate clinical outcomes such as bleeding and need for transfusions.
Collapse
Affiliation(s)
- Adrian Wong
- NYU Langone Health - Department of Pharmacy, New York, NY, USA
| | - Tania Ahuja
- NYU Langone Health - Department of Pharmacy, New York, NY, USA
| | - Frank Cirrone
- Perlmutter Cancer Center - Department of Pharmacy, New York, NY, USA
| | - Elaine Xiang
- NYU Langone Health - Department of Pharmacy, New York, NY, USA
| |
Collapse
|
2
|
Abdelmessih E, Ahuja T, Wo S, Sango A, Papadopoulos J, Green D, Xiang E. Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases. J Thromb Thrombolysis 2024; 57:418-427. [PMID: 38281232 DOI: 10.1007/s11239-023-02936-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/17/2023] [Indexed: 01/30/2024]
Abstract
To evaluate the safety of direct oral anticoagulants (DOACs) versus low-molecular weight heparin (LMWH) in patients with central nervous system (CNS) malignancies and secondary metastases. All adult patients with CNS malignancies and secondary metastases who were treated with a DOAC or LMWH for any indication from 2018 to 2022 were included. The primary outcome was the incidence of any intracranial hemorrhage (ICH) after anticoagulation initiation. Secondary outcomes included non-ICH bleeding events and thromboembolic events. Tolerability was assessed by any changes in anticoagulant therapy during study period. 153 patients were included; 48 patients received enoxaparin and 105 received DOACs, of which apixaban was used most commonly. The population was predominantly White (74%) and male (59%) with a median age of 65. Data was censored for immortal time bias for outcomes evaluated beyond 3 months. ICH occurred in 7.7% of the population, more frequently in the enoxaparin group (DOACs 4, 4% vs. enoxaparin 7, 16%, p = 0.037). Non-ICH bleeds were predominantly minor and more common in the DOAC group (DOACs 13, 13% vs. enoxaparin 1, 2%, p = 0.037). Thromboembolic events were not different between groups (DOACs 9. 9% vs, enoxaparin 2, 4%, p = 0.503). Anticoagulant switches occurred more in the enoxaparin group (DOACs 12, 12.4% vs. enoxaparin, 37.8%, p < 0.001), primarily due to patient or provider preference. Our data supports DOACs to be preferred over LMWH for the treatment of VTE or for stroke prevention with AF to prevent ICH in patients with brain tumors or metastases.
Collapse
Affiliation(s)
- Emily Abdelmessih
- Department of Pharmacy, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| | - Tania Ahuja
- Department of Pharmacy, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.
- Department of Medicine NYU Grossman School of Medicine, 550 First Avenue, New York, NY, 10016, USA.
| | - Stephanie Wo
- Department of Pharmacy, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| | - Aaron Sango
- Department of Pharmacy, NYU Langone Health, 150 55th Street, Brooklyn, NY, 11220, USA
| | - John Papadopoulos
- Department of Pharmacy, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
- Department of Medicine NYU Grossman School of Medicine, 550 First Avenue, New York, NY, 10016, USA
| | - David Green
- Department of Medicine NYU Grossman School of Medicine, 550 First Avenue, New York, NY, 10016, USA
| | - Elaine Xiang
- Department of Pharmacy, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| |
Collapse
|
3
|
He J, Wang Z, Ao C, Tu C, Zhang Y, Chang C, Xiao C, Xiang E, Rao W, Li C, Wu D. A highly sensitive and specific Homo1-based real-time qPCR method for quantification of human umbilical cord mesenchymal stem cells in rats. Biotechnol J 2024; 19:e2300484. [PMID: 38403446 DOI: 10.1002/biot.202300484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 12/17/2023] [Accepted: 12/27/2023] [Indexed: 02/27/2024]
Abstract
BACKGROUND Owing to the characteristics of easier access in vitro, low immunogenicity, and high plasticity, human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are considered as a promising cell-based drugs for clinical application. No internationally recognized technology exists to evaluate the pharmacokinetics and distribution of cell-based drugs in vivo. METHODS We determined the human-specific gene sequence, Homo1, from differential fragments Homo sapiens mitochondrion and Rattus norvegicus mitochondrion. The expression of Homo1 was utilized to determine the distribution of UC-MSCs in the normal and diabetic nephropathy (DN) rats. RESULTS We observed a significant correlation between the number of UC-MSCs and the expression level of Homo1. Following intravenous transplantation, the blood levels of UC-MSCs peaked at 30 min. A large amount of intravenously injected MSCs were trapped in the lungs, but the number of them decreased rapidly after 24 h. Additionally, the distribution of UC-MSCs in the kidneys of DN rats was significantly higher than that of normal rats. CONCLUSIONS In this study, we establish a highly sensitive and specific Homo1-based real-time quantitative PCR method to quantify the distribution of human UC-MSCs in rats. The method provides guidelines for the safety research of cells in preclinical stages.
Collapse
Affiliation(s)
- Jing He
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Zhangfan Wang
- R&D Center, Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Chunchun Ao
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Chengshu Tu
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yaqi Zhang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Cheng Chang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Cuihong Xiao
- R&D Center, Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - E Xiang
- R&D Center, Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Wei Rao
- R&D Center, Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Changyong Li
- Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, China
- Xianning Medical College, Hubei University of Science & Technology, Xianning, China
| | - Dongcheng Wu
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
- R&D Center, Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
- R&D Center, Guangzhou Hamilton Biotechnology Co., Ltd, Guangzhou, China
| |
Collapse
|
4
|
Wang A, Cirrone F, De Los Reyes FA, Papadopoulos J, Saint Fleur-Lominy S, Xiang E. High-dose methotrexate dosing strategy in primary central nervous system lymphoma. Leuk Lymphoma 2022; 63:1348-1355. [PMID: 35120432 DOI: 10.1080/10428194.2021.2024818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The backbone induction therapy for primary central nervous system lymphoma (PCNSL) is high dose methotrexate (HD-MTX) and rituximab, which can be combined with other chemotherapeutic agents. The optimal dose of HD-MTX remains unclear, as doses between 3 and 8 g/m2 have been shown to be effective. In this retrospective study, HD-MTX dosed at 3-5 g/m2 demonstrated an overall response of 81.8%, with 11 (50%) complete responses. The median overall survival was not met at 29 months and median progression free survival was 12.5 months.There were two discontinuations due to nephrotoxicity. The most common adverse event was hepatotoxicity (18.5%), with no treatment-related mortality events observed.Overall, HD-MTX dosed at 3-5 g/m2 demonstrated similar efficacy and lower toxicity compared to higher doses in PCNSL patients. Reducing the initial HD-MTX dose may help ensure tolerability and completion of induction therapy, especially in patients with co-morbidities or older age who have poorer outcomes.
Collapse
Affiliation(s)
- Alexander Wang
- Department of Pharmacy, NYU Langone Health, New York, NY, USA
| | - Frank Cirrone
- Department of Pharmacy, NYU Langone Health, New York, NY, USA
| | | | - John Papadopoulos
- Department of Pharmacy, NYU Langone Health, New York, NY, USA.,Department of Medicine, NYU Langone Health, New York, NY, USA
| | | | - Elaine Xiang
- Department of Pharmacy, NYU Langone Health, New York, NY, USA
| |
Collapse
|
5
|
Tu C, Wang Z, Xiang E, Zhang Q, Zhang Y, Wu P, Li C, Wu D. Human Umbilical Cord Mesenchymal Stem Cells Promote Macrophage PD-L1 Expression and Attenuate Acute Lung Injury in Mice. Curr Stem Cell Res Ther 2022; 17:564-575. [PMID: 35086457 DOI: 10.2174/1574888x17666220127110332] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 11/11/2021] [Accepted: 12/19/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) remains a serious clinical problem but has no approved pharmacotherapy. Mesenchymal stem cells (MSCs) represent an attractive therapeutic tool for tissue damage and inflammation owing to their unique immunomodulatory properties. The present study aims to explore the therapeutic effect and underlying mechanisms of human umbilical cord MSCs (UC-MSCs) in ALI mice. OBJECTIVE In this study, we identify a novel mechanism for human umbilical cord-derived MSCs (UC-MSCs)-mediated immunomodulation through PGE2-dependent reprogramming of host macrophages to promote their PD-L1 expression. Our study suggests that UC-MSCs or primed-UC-MSCs offer new therapeutic approaches for lung inflammatory diseases. METHODS Lipopolysaccharide (LPS)-induced ALI mice were injected with 5×105 UC-MSCs via the tail vein after 4 hours of LPS exposure. After 24 hours of UC-MSC administration, the total protein concentration and cell number in the bronchoalveolar lavage fluid (BALF), and cytokine levels in the lung tissue were measured. Lung pathological changes and macrophage infiltration after UC-MSC treatment were analyzed. Moreover, in vitro co-culture experiments were performed to analyze cytokine levels of RAW264.7 cells and Jurkat T cells. RESULTS UC-MSC treatment significantly improved LPS-induced ALI, as indicated by decreased total protein exudation concentration and cell number in BALF, and reduced pathological damage in ALI mice. UC-MSCs could inhibit pro-inflammatory cytokine levels (IL-1β, TNF-α, MCP-1, IL-2, and IFN-γ), whereas enhancing anti-inflammatory cytokine IL-10 expression, as well as reduced macrophage infiltration into the injured lung tissue. Importantly, UC-MSC administration increased programmed cell death protein ligand 1 (PD-L1) expression in the lung macrophages. Mechanistically, UC-MSCs upregulated cyclooxygenase-2 (COX2) expression and prostaglandin E2 (PGE2) secretion in response to LPS stimulation. UC-MSCs reduced the inflammatory cytokine levels in murine macrophage Raw264.7 through the COX2/PGE2 axis. Furthermore, UC-MSC-derived PGE2 enhanced PD-L1 expression in RAW264.7 cells, which in turn promoted programmed cell death protein 1 (PD-1) expression and reduced IL-2 and IFN-γ production in Jurkat T cells. CONCLUSION Our results suggest that UC-MSCs attenuate ALI via PGE2-dependent reprogramming of macrophages to promote their PD-L1 expression.
Collapse
Affiliation(s)
- Chengshu Tu
- Department of Pathophysiology, Tongji Medical College, Huazhong Science and Technology University, Wuhan, China
| | | | - E Xiang
- Wuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Quan Zhang
- Wuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China
| | - Yaqi Zhang
- Wuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Ping Wu
- Department of Pathophysiology, Tongji Medical College, Huazhong Science and Technology University, Wuhan, China
| | - Changyong Li
- Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Dongcheng Wu
- Wuhan Hamilton Biotechnology-Co., Ltd, Wuhan, China
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
- Guangzhou Hamilton Biotechnology-Co., Ltd, Guangzhou, China
| |
Collapse
|
6
|
Zhang Q, Xiang E, Rao W, Zhang YQ, Xiao CH, Li CY, Han B, Wu D. Intra-articular injection of human umbilical cord mesenchymal stem cells ameliorates monosodium iodoacetate-induced osteoarthritis in rats by inhibiting cartilage degradation and inflammation. Bone Joint Res 2021; 10:226-236. [PMID: 33739851 PMCID: PMC7998343 DOI: 10.1302/2046-3758.103.bjr-2020-0206.r2] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Aims This study aimed to investigate whether human umbilical cord mesenchymal stem cells (UC-MSCs) can prevent articular cartilage degradation and explore the underlying mechanisms in a rat osteoarthritis (OA) model induced by monosodium iodoacetate (MIA). Methods Human UC-MSCs were characterized by their phenotype and multilineage differentiation potential. Two weeks after MIA induction in rats, human UC-MSCs were intra-articularly injected once a week for three weeks. The therapeutic effect of human UC-MSCs was evaluated by haematoxylin and eosin, toluidine blue, Safranin-O/Fast green staining, and Mankin scores. Markers of joint cartilage injury and pro- and anti-inflammatory markers were detected by immunohistochemistry. Results Histopathological analysis showed that intra-articular injection of human UC-MSCs significantly inhibited the progression of OA, as demonstrated by reduced cartilage degradation, increased Safranin-O staining, and lower Mankin scores. Immunohistochemistry showed that human UC-MSC treatment down-regulated the expression of matrix metalloproteinase-13 (MMP13) and a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5), and enhanced the expression of type II collagen and ki67 in the articular cartilage. Furthermore, human UC-MSCs significantly decreased the expression of interleukin (IL)-1β and tumour necrosis factor-α (TNF-α), while increasing TNF-α-induced protein 6 and IL-1 receptor antagonist. Conclusion Our results demonstrated that human UC-MSCs ameliorate MIA-induced OA by preventing cartilage degradation, restoring the proliferation of chondrocytes, and inhibiting the inflammatory response, which implies that human UC-MSCs may be a promising strategy for the treatment of OA. Cite this article: Bone Joint Res 2021;10(3):226–236.
Collapse
Affiliation(s)
- Quan Zhang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.,Wuhan Hamilton Biotechnology Co, Wuhan, China
| | - E Xiang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.,Wuhan Hamilton Biotechnology Co, Wuhan, China
| | - Wei Rao
- Wuhan Hamilton Biotechnology Co, Wuhan, China
| | - Ya Qi Zhang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | | | - Chang Yong Li
- Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Bing Han
- Wuhan Hamilton Biotechnology Co, Wuhan, China
| | - Dongcheng Wu
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.,Wuhan Hamilton Biotechnology Co, Wuhan, China
| |
Collapse
|
7
|
Dai Y, Luo J, Xiang E, Guo Q, He Z, Gong Z, Sun X, Kou H, Xu K, Fan C, Liu J, Qiu S, Wang Y, Wang H, Guo Y. Prenatal Exposure to Retrorsine Induces Developmental Toxicity and Hepatotoxicity of Fetal Rats in a Sex-Dependent Manner: The Role of Pregnane X Receptor Activation. J Agric Food Chem 2021; 69:3219-3231. [PMID: 33685126 DOI: 10.1021/acs.jafc.0c06748] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Pyrrolizidine alkaloids (PAs) are a type of natural phytotoxin that contaminate food and feed and become an environmental health risk to humans and livestock. PAs exert toxicity that requires metabolic activation by cytochrome P450 (CYP) 3A, and case reports showed that fetuses are quite susceptible to PAs toxicity. The aim of this study was to explore the characteristics of developmental toxicity and fetal hepatotoxicity induced by retrorsine (RTS, a typcial toxic PA) and the underlying mechanism. Pregnant Wistar rats were intragastrically administered with 20 mg/(kg·day) RTS from gestation day (GD) 9 to 20. Results showed that prenatal RTS exposure lowered fetal bodyweights, reduced hepatocyte numbers, and potentiated hepatic apoptosis in fetuses, particularly females. Simutaneously, RTS increased CYP3A expression and pregnane X receptor (PXR) activation in female fetal liver. We further confirmed that RTS was a PXR agonist in LO2 and HepG2 cell lines. Furthermore, agonism or antagonism of androgen receptor (AR) either induced or blocked RTS-mediated PXR activation, respectively. As a PXR agonist, RTS toxicity was exacerbated in female fetus due to the increased CYP3A induction and self-metabolism, while the inhibitory effect of AR on PXR activation reduced the susceptibility of male fetus to RTS. Our findings indicated that PXR may be a potential therapeutic target for PA toxicity.
Collapse
Affiliation(s)
- Yongguo Dai
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Jinyuan Luo
- Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei Province, China
| | - E Xiang
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Qi Guo
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Zheng He
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
| | - Zheng Gong
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Xiaoxiang Sun
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Hao Kou
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
- Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei Province, China
| | - Kequan Xu
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Chengpeng Fan
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
| | - Jie Liu
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Shuaikai Qiu
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Yanqing Wang
- Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei Province, China
| | - Hui Wang
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| | - Yu Guo
- Department of Pharmacology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei Province, China
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071 Hubei Province, China
| |
Collapse
|
8
|
Soskind R, Xiang E, Lewis T, Al-Homsi AS, Papadopoulos J, Cirrone F. Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation. J Oncol Pharm Pract 2020; 27:1447-1453. [PMID: 32957861 DOI: 10.1177/1078155220959416] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tacrolimus is a mainstay medication for graft-versus-host disease (GVHD) prophylaxis in combination with other immunosuppressive agents. Achieving therapeutic tacrolimus levels is vital in preventing acute GVHD (aGVHD), while supratherapeutic levels may increase risk of toxicity and relapse. We performed a single center retrospective chart review including all adult patients post-allogeneic hematopoietic stem-cell transplantation who received initial tacrolimus continuous intravenous infusion for GVHD prophylaxis between June 1, 2017 and December 31, 2019. The primary outcome was the percent of patients with an initial therapeutic tacrolimus level, defined as 5-12 ng/mL, after empiric weight-based dosing at 0.02 mg/kg/day. Secondary outcomes included evidence of tacrolimus toxicity within seven days of initiation, incidence of aGVHD by day 100, and relapse after six months. An initial therapeutic level was achieved in 47% of patients with a median initial level of 12.4 ng/mL. Fifty-two percent of patients had supratherapeutic levels. No significant nephrotoxicity, hepatotoxicity, or neurotoxicity occurred within a week of starting tacrolimus or at neutrophil engraftment. Grade II-IV aGVHD by day 100 was observed in 22% of patients, and relapse after six months was found in 16% of patients. These results have led to consideration of an empiric 20% dose reduction to 0.016 mg/kg/day or an expanded initial tacrolimus target of 5-15 ng/mL as there was low aGVHD incidence and no increased risk of toxicity.
Collapse
|
9
|
Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C, Zhang Y, Tu C, Li C, Wu D. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther 2020; 11:336. [PMID: 32746936 PMCID: PMC7397631 DOI: 10.1186/s13287-020-01852-y] [Citation(s) in RCA: 114] [Impact Index Per Article: 28.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 07/01/2020] [Accepted: 07/24/2020] [Indexed: 12/11/2022] Open
Abstract
Background Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. Currently, there are no effective drugs for treating DN. Therefore, novel and effective strategies to ameliorate DN at the early stage should be identified. This study aimed to explore the effectiveness and underlying mechanisms of human umbilical cord mesenchymal stem cells (UC-MSCs) in DN. Methods We identified the basic biological properties and examined the multilineage differentiation potential of UC-MSCs. Streptozotocin (STZ)-induced DN rats were infused with 2 × 106 UC-MSCs via the tail vein at week 6. After 2 weeks, we measured blood glucose level, levels of renal function parameters in the blood and urine, and cytokine levels in the kidney and blood, and analyzed renal pathological changes after UC-MSC treatment. We also determined the colonization of UC-MSCs in the kidney with or without STZ injection. Moreover, in vitro experiments were performed to analyze cytokine levels of renal tubular epithelial cell lines (NRK-52E, HK2) and human renal glomerular endothelial cell line (hrGECs). Results UC-MSCs significantly ameliorated functional parameters, such as 24-h urinary protein, creatinine clearance rate, serum creatinine, urea nitrogen, and renal hypertrophy index. Pathological changes in the kidney were manifested by significant reductions in renal vacuole degeneration, inflammatory cell infiltration, and renal interstitial fibrosis after UC-MSC treatment. We observed that the number of UC-MSCs recruited to the injured kidneys was increased compared with the controls. UC-MSCs apparently reduced the levels of pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) and pro-fibrotic factor (TGF-β) in the kidney and blood of DN rats. In vitro experiments showed that UC-MSC conditioned medium and UC-MSC-derived exosomes decreased the production of these cytokines in high glucose-injured renal tubular epithelial cells, and renal glomerular endothelial cells. Moreover, UC-MSCs secreted large amounts of growth factors including epidermal growth factor, fibroblast growth factor, hepatocyte growth factor, and vascular endothelial growth factor. Conclusion UC-MSCs can effectively improve the renal function, inhibit inflammation and fibrosis, and prevent its progression in a model of diabetes-induced chronic renal injury, indicating that UC-MSCs could be a promising treatment strategy for DN.
Collapse
Affiliation(s)
- E Xiang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.,Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Bing Han
- Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Quan Zhang
- Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Wei Rao
- Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | | | - Cheng Chang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Yaqi Zhang
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Chengshu Tu
- Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China
| | - Changyong Li
- Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
| | - Dongcheng Wu
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China. .,Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China.
| |
Collapse
|
10
|
Chen L, Xiang E, Li C, Han B, Zhang Q, Rao W, Xiao C, Wu D. Umbilical Cord-Derived Mesenchymal Stem Cells Ameliorate Nephrocyte Injury and Proteinuria in a Diabetic Nephropathy Rat Model. J Diabetes Res 2020; 2020:8035853. [PMID: 32405507 PMCID: PMC7206880 DOI: 10.1155/2020/8035853] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 03/30/2020] [Indexed: 12/21/2022] Open
Abstract
Mesenchymal stem cells (MSCs) are shown to alleviate renal injury of diabetic nephropathy (DN) in rats. However, the underlying mechanism of this beneficial effect is not fully understood. The aims of this study are to evaluate effects of umbilical cord-derived mesenchymal stem cells (UC-MSCs) on renal cell apoptosis in streptozotocin- (STZ-) induced diabetic rats and explore the underlying mechanisms. Characteristics of UC-MSCs were identified by flow cytometry and differentiation capability. Six weeks after DN induction by STZ injection in Sprague-Dawley rats, the DN rats received UC-MSCs once a week for consecutive two weeks. DN-related physical and biochemical parameters were measured at 2 weeks after UC-MSC infusion. Renal histological changes were also assessed. Moreover, the apoptosis of renal cells and expression of apoptosis-related proteins were evaluated. Compared with DN rats, rats treated with UC-MSCs showed suppressed increase in 24-hour urinary total protein, urinary albumin to creatinine ratio, serum creatinine, and blood urea nitrogen. UC-MSC treatment ameliorated pathological abnormalities in the kidney of DN rats as evidenced by H&E, PAS, and Masson Trichrome staining. Furthermore, UC-MSC treatment reduced apoptosis of renal cells in DN rats. UC-MSCs promoted expression of antiapoptosis protein Bcl-xl and suppressed expression of high mobility group protein B1 (HMGB1) in the kidney of DN rats. Most importantly, UC-MSCs suppressed upregulation of thioredoxin-interacting protein (TXNIP), downregulation of thioredoxin 1 (TRX1), and activation of apoptosis signal-regulating kinase 1 (ASK1) and P38 MAPK in the kidney of DN rats. Our results suggest that UC-MSCs could alleviate nephrocyte injury and albuminuria of DN rats through their antiapoptotic property. The protective effects of UC-MSCs may be mediated by inhibiting TXNIP upregulation in part.
Collapse
Affiliation(s)
- Lian Chen
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - E. Xiang
- Wuhan Hamilton Biotechnology Co., Ltd., Wuhan, China
| | - Changyong Li
- Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, China
| | - Bing Han
- Wuhan Hamilton Biotechnology Co., Ltd., Wuhan, China
| | - Quan Zhang
- Wuhan Hamilton Biotechnology Co., Ltd., Wuhan, China
| | - Wei Rao
- Wuhan Hamilton Biotechnology Co., Ltd., Wuhan, China
| | - Cuihong Xiao
- Wuhan Hamilton Biotechnology Co., Ltd., Wuhan, China
| | - Dongcheng Wu
- Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China
- Wuhan Hamilton Biotechnology Co., Ltd., Wuhan, China
| |
Collapse
|
11
|
Luo J, Yang X, Qiu S, Li X, Xiang E, Fang Y, Wang Y, Zhang L, Wang H, Zheng J, Guo Y. Sex difference in monocrotaline-induced developmental toxicity and fetal hepatotoxicity in rats. Toxicology 2019; 418:32-40. [PMID: 30825512 DOI: 10.1016/j.tox.2019.02.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Revised: 02/20/2019] [Accepted: 02/25/2019] [Indexed: 12/15/2022]
Abstract
Pyrrolizidine alkaloids (PAs) are a class of hepatic toxins widely existing in plants. Cytochromes P450 (CYP) mediates PA bioactivation and toxicities in mammals. It has been reported that PAs can induce developmental toxicity, but systematic research is lacking. In this study, we investigated developmental toxicity of monocrotaline (MCT) in rats. Pregnant rats were administered with MCT (20 mg/kg) intragastrically from gestation day 9 to 20, followed by determination of changes in fetal growth, hepatic morphology, serum biochemical indices, and indicators of hepatocytes apoptosis. MCT was found to induce developmental toxicity and fetal hepatotoxicity, particularly in female fetuses. Metabolic activation was also studied by examination of bioactivation efficiency of MCT in fetal liver microsomes, serum MCT, pyrrole-protein adduction derived from MCT, and hepatic CYP3 A expression of fetuses in vivo. Male fetuses showed greater basal MCT bioactivation than that of female fetuses, but continuous exposure to MCT caused a selective CYP3 A induction in female fetuses, which may contribute to the sex difference in MCT-induced developmental toxicity.
Collapse
Affiliation(s)
- Jinyuan Luo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Xiaojing Yang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, People's Republic of China.
| | - Shuaikai Qiu
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Xia Li
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - E Xiang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Yan Fang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Yanqing Wang
- Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan 430060, People's Republic of China.
| | - Li Zhang
- Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China.
| | - Hui Wang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| | - Jiang Zheng
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, People's Republic of China; State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China; Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
| | - Yu Guo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, People's Republic of China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, People's Republic of China.
| |
Collapse
|
12
|
Abstract
INTRODUCTION For multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard of care with high-dose melphalan for transplant candidates. There are now two different melphalan formulations available, including a propylene glycol containing (PG-MEL) product and a propylene glycol-free (PG-free MEL) product. Although considered bioequivalent, there remains limited literature directly evaluating the adverse events between the two agents. We seek to assess the tolerability and severity of side effects between the two formulations in a real-life practice setting. METHODS A retrospective, descriptive analysis was conducted of multiple myeloma patients who received autologous stem cell conditioning with either melphalan formulation when dosed at 100 mg/m2/dose for two consecutive doses. The primary outcome was the assessment of tolerability and severity of side effects. Tolerability was split into four major categories including hematologic toxicity, gastrointestinal toxicity, renal toxicity, and highest recorded mucositis grade. RESULTS There were a total of 78 patients who received a melphalan preparation during the study. The median time to myeloablation and neutrophil engraftment was five and seven days post-HSCT, respectively, for all patients. Patients who received PG-free MEL were less likely to develop mucositis, with 22 (56%) reported highest grade 0, defined by World Health Organization oral toxicity scale, compared to those who received PG-MEL (33%), p = 0.04. CONCLUSION There were minimal differences in tolerability or side effects observed between PG-free MEL and PG-MEL. These data may assist in better understanding the anticipated adverse effects of a high-dose melphalan conditioning therapy.
Collapse
Affiliation(s)
- Elaine Xiang
- 1 Department of Pharmacy, Dana Farber Cancer Institute, Boston, MA, USA
| | - Jian Ni
- 2 Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA
| | - Brett Glotzbecker
- 3 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
| | - Jacob Laubach
- 3 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
| | - Robert Soiffer
- 3 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
| | - Anne M McDonnell
- 2 Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA
| |
Collapse
|
13
|
Abstract
Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE). Low molecular weight heparin remains the preferred anticoagulant for VTE in patients with cancer over vitamin K antagonist. However, the preferred anticoagulant in prevention of stroke and systemic embolism in atrial fibrillation (AF) in patients with cancer has yet to be determined. The direct oral anticoagulants (DOACs) are increasingly being utilized; however their role in cancer has only recently been investigated. The objective of this retrospective cohort was to describe real-world anticoagulation prescribing patterns in cancer patients at a large academic medical center between January 1, 2013 and October 31, 2016. We sought to assess the safety, tolerability, and efficacy of DOACs in patients with cancer for either VTE and/or AF. Patient demographic, clinical characteristics, as well as bleeding and thrombotic events were collected. There were 214 patients in our analysis, of which 71 patients (33%) received a DOAC [apixaban (n = 22), dabigatran (n = 17), and rivaroxaban (n = 32)]. There were fewer bleeding events and/or discontinuations in the DOAC group compared to enoxaparin (13 vs. 27, p = 0.022). There was no difference in major or minor bleeds or thromboembolic events in comparing DOAC to enoxaparin or DOAC to warfarin. This was a retrospective, single-institution study assessing the safety and efficacy of DOACs compared to warfarin or enoxaparin in patients with cancer. DOACs may represent an alternative to warfarin or enoxaparin in patients with cancer for VTE and/or stroke reduction in AF.
Collapse
Affiliation(s)
- Elaine Xiang
- Department of Pharmacy, PGY-1 Pharmacy Resident, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| | - Tania Ahuja
- Department of Pharmacy, Clinical Pharmacotherapy Manager: Internal Medicine & Anticoagulation, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.
| | - Veronica Raco
- Department of Pharmacy, Clinical Pharmacotherapy Specialist: Internal Medicine, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| | - Frank Cirrone
- Department of Pharmacy, Clinical Pharmacotherapy Manager: Heamtology/Oncology, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| | - David Green
- Department of Medicine, Antithrombotic Therapy Team, Medical Director, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| | - John Papadopoulos
- Department of Pharmacy, Director of Clinical Pharmacy Services, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA
| |
Collapse
|
14
|
Li X, Yang X, Xiang E, Luo J, Qiu S, Fang Y, Zhang L, Guo Y, Zheng J, Wang H. Maternal-Fetal Disposition and Metabolism of Retrorsine in Pregnant Rats. Drug Metab Dispos 2018; 46:422-428. [PMID: 29352068 DOI: 10.1124/dmd.117.079186] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 01/17/2018] [Indexed: 11/22/2022] Open
Abstract
Pyrrolizidine alkaloids (PAs) are extensively synthesized by plants, are commonly present in herbs and foodstuffs, and exhibit hepatotoxicity requiring metabolic activation by cytochrome P450 3A to form the electrophilic metabolites-pyrrolic esters. PAs also cause embryo toxicity, but the metabolic profiles of PAs in fetus and placenta have been far from clear. In this study, we determined the basal metabolic activation of retrorsine (RTS) in rat maternal liver, placenta, and fetal liver in vitro and examined the fetal toxicity and bioactivation of RTS in vivo. Detection of microsomal RTS metabolites in vitro showed that the basal metabolic activity of fetal liver and placenta to RTS was much weaker than that of maternal liver. In addition, a higher rate of pyrrolic ester formation was found in normal male fetal liver compared with that of female pups. In vivo exposure to RTS caused fetal growth retardation, as well as placental and fetal liver injury. Little difference in serum RTS was observed in dams and fetuses, but the content of pyrrole-protein adduction in the fetal liver was much lower than that in maternal liver, which was consistent with basal metabolic activity. Unexpectedly, compared with basal metabolism in fetal liver, exposure to RTS during middle and late pregnancy caused an opposite gender difference in RTS metabolism and CYP3A expression in the fetal liver. For the first time, our study showed that RTS can permeate the placenta barrier and entering fetal circulation, whereas the intrauterine pyrrolic metabolite was generated mainly by fetal liver but not transported from the maternal circulation. Induction of CYP3A by RTS was gender-dependent in the fetal liver, which was probably responsible for RTS-induced fetal hepatic injury, especially for female pups.
Collapse
Affiliation(s)
- Xia Li
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Xiaojing Yang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - E Xiang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Jinyuan Luo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Shuaikai Qiu
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Yan Fang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Li Zhang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Yu Guo
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Jiang Zheng
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| | - Hui Wang
- Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan (X.L., E.X., J.L., S.Q., Y.F., Y.G., H.W.); and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University, Wuhan (Y.G., H.W.); Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning (X.Y., J.Z.); and State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou (J.Z.); Department of Pathology, School of Basic Medical Science, Wuhan University, Wuhan (L.Z.), China
| |
Collapse
|
15
|
Hoff T, Young G, Xiang E, Raver E. Understanding U.S. Physician Satisfaction: State of the Evidence and Future Directions. J Healthc Manag 2015; 60:409-427. [PMID: 26720985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Physician satisfaction is an important issue, yet we know less about it than we should. This narrative review updates our knowledge about U.S. physician satisfaction and proposes new foci for understanding and studying the topic that align better with the evolving U.S. healthcare delivery system, physicians' everyday work situations, and medicine's internal demographic changes. Using the PubMed database of empirical studies published between 2008 and 2013 that examine U.S. physician job, career, or work satisfaction, we compare our review findings with a review covering studies published between 1970 and 2007. We included 22 studies in our review. Overall, U.S. physicians experience moderate to high levels of job, work, and career satisfaction, and these levels have remained stable over time. This is surprising given discussions in the popular press of declining physician satisfaction. The observed consistency and the high levels of satisfaction do not tell the entire story. While autonomy, income, and perceived job demands are several of the stronger predictors of physician satisfaction, variables such as age and gender have been understudied. And our understanding of what drives physician satisfaction still draws too heavily on other variables that are less salient given today's workplace and the current trends in professional demographics and employment arrangements. Future thinking and research on physician satisfaction should align more with the array of changes now occurring within the U.S. medical profession and the larger U.S. healthcare delivery system, within which physicians work. To do this, new variables and conceptual thinking that capture these changes must be used.
Collapse
|